Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Primary result · Change in LDL-CResult — go to the resultPlacebo-adjusted change −36.3 % 95% CI −42.2% to −30.4%Authors' conclusion
These findings suggest that obicetrapib is an effective therapy for additional lipid lowering in patients with heterozygous familial hypercholesterolemia.
Study context
- Population
- Heterozygous familial hypercholesterolemia with LDL-C ≥70 mg dl-1 on maximally tolerated lipid-lowering therapy190 women · 164 men
- Participants
- 354 participants
- Comparison
- Obicetrapib 10 mg daily vs placebo
- Primary endpoint
- Change in LDL-C from baseline
- Follow-up
- Day 84
Methodological detailsplacebo-controlled, 2:1 randomisation
- Placebo-controlled
- 2:1 randomisation
Primary result
Change in LDL-C
Placebo-adjusted change
−36.3 %
95% CI −42.2% to −30.4%
P < 0.0001
Obicetrapib vs Placebo
placebo-adjusted change −36.3 % (95% CI −42.2% to −30.4%); P < 0.0001
As reported in the abstract
Secondary outcomes
Apolipoprotein B, non-HDL cholesterol, lipoprotein(a), HDL-C · day 84
- Placebo-adjusted change in apolipoprotein B
- −24.4%
- Placebo-adjusted change in non-HDL cholesterol
- −34.5%
- Placebo-adjusted change in lipoprotein(a)
- −45.9%
- Placebo-adjusted change in HDL-C
- +138.7%
Original publication
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. Published 27 February 2026. doi:10.
Summarised from the published abstract; every number is checked against it